top of page

NEWS

This page features the latest from NeoVac. Press releases, milestones, conference news and selected articles. For scientific outputs, please see Publications.

Preparing for a Modern Plague Threat: NeoVac’s mRNA Vaccine Approach

October 5, 2026
Plague remains a modern global health and biosecurity concern. Discover how NeoVac is advancing mRNA-based vaccines against bubonic and pneumonic plague, while exploring the potential of mRNA technology to strengthen preparedness for emerging infectious disease threats.
READ MORE

NeoVac Announces Positive Phase I/II Results Demonstrating Superior Safety Profile of Next-Generation mRNA-LNP Vaccine Platform

February 05, 2026
First-in-Human Phase I/II Results of Proprietary Lipid Nanoparticle Delivery Platform Advance the Potential of mRNA Therapeutics and Preventive Vaccines
READ MORE

NeoVac announces new CEO

September 16, 2026
NeoVac, a leading pharmaceutical company specialising in innovative lipid nanoparticle (LNP) technologies for mRNA therapeutics, is pleased to announce the appointment of Dr. Jan H. Egberts as Chief Executive Officer to guide the next phase of growth for the company
READ MORE
bottom of page